Imatinib
| Evidence Level: L5 | Predicted Indications: 56 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Imatinib |
| DrugBank ID | DB00619 |
| Brand Names (EU) | Glivec, Imatinib Accord, Imatinib Teva |
| Evidence Level | L5 |
| Predicted Indications | 56 |
| Top Prediction Score | 99.99% |
Approved Indication (EMA)
Imatinib Teva is indicated for the treatment of Adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr?abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. Adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon?alpha therapy, or in accelerated phase or blast crisis. Adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acut
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | dermatofibrosarcoma protuberans | 99.99% | DL |
| 2 | heart fibrosarcoma | 99.94% | DL |
| 3 | fibroblastic neoplasm | 99.94% | DL |
| 4 | conventional fibrosarcoma | 99.93% | DL |
| 5 | kidney fibrosarcoma | 99.93% | DL |
| 6 | low grade fibromyxoid sarcoma | 99.93% | DL |
| 7 | liposarcoma | 99.88% | DL |
| 8 | liver fibrosarcoma | 99.86% | DL |
| 9 | autosomal recessive familial Mediterranean fever | 99.86% | DL |
| 10 | ovarian myxoid liposarcoma | 99.85% | DL |
| 11 | familial rhabdoid tumor | 99.83% | DL |
| 12 | benign PEComa | 99.81% | DL |
| 13 | uterine corpus perivascular epithelioid cell tumor | 99.81% | DL |
| 14 | lymphangiomyoma | 99.80% | DL |
| 15 | lymphangioleiomyomatosis | 99.77% | DL |
| 16 | bone fibrosarcoma | 99.75% | DL |
| 17 | cutaneous undifferentiated pleomorphic sarcoma | 99.74% | DL |
| 18 | cutaneous leiomyosarcoma (disease) | 99.73% | DL |
| 19 | central nervous system fibrosarcoma | 99.72% | DL |
| 20 | vulva sarcoma | 99.67% | DL |
Showing top 20 of 56 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.